Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Diagnostic Radiologists :Nuclear Radiology

Articles with lock require a subscription to GLG News | Request a free trial
August 8, 2008
Federal Govt. Should be the cost
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor
1. Kidney cancer drugs have the potential to extend progression-free survival by five to six months, but at a cost of $40,000 to $70,000 per patient per year.  2. The cost per quality adjusted life year (QALY) gained of these treatments is between $57,000 and $180,000 per patient - based on...
August 7, 2008
FDA will ask for more data
Analysis of: AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes | www.astrazeneca.com
Author: GLG Expert Contributor
Saxagliptin is being studied in clinical trials as a once-daily therapy to determine its efficacy and safety. Saxagliptin was specifically designed to be a selective, reversible inhibitor of the DPP-4 enzyme, with dual routes of clearance. Phase III data for saxagliptin have previously been presented...
August 6, 2008
HIV drugs can not be used as prevention
Analysis of: Researchers Look to Pill, Taken Daily, to Avert H.I.V. | www.nytimes.com
Author: GLG Expert Contributor
1.PrEP involves a prescription drug, so it’s likely that initial programs will be clinic-based. PrEP delivery would also require periodic HIV testing. 2. In contrast to male circumcision—or hopefully one day, a vaccine—PrEP would require that people take a drug on an ongoing basis (daily or intermittently)....
July 31, 2008
Sepsis biomarker
Analysis of: SIRS-Lab Pre-Announces Biomarker Based Sepsis Test | www.medcompare.com
Author: GLG Expert Contributor
1.Reliable biomarkers for the early observation of the inflammation status of sepsis are urgently needed. 2. SIQNATURE has major potential to improve the treatment of severe sepsis by the early identification of patients at risk.
July 29, 2008
Relationship between Angiotensin receptor blocker and Alzheime's disease
Analysis of: Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com
Author: GLG Expert Contributor
 This article is important because it  opened a new  avenue to do more research to find  relationship between Relationship between Angiotensin receptor blocker and Alzheime's disease.
July 28, 2008
APOSENSE® [18F]-ML-10- A novel Apoptosis Imaging Agent
Analysis of: APOSENSE® [18F]-ML-10 For Molecular Imaging Of Apoptosis To Proceed To Phase I/II Trials | www.medicalnewstoday.com
Author: GLG Expert Contributor
This  is  very good news  that FDA  approved the letter for clinical trial of APOSENSE® [18F]-ML-10:
July 22, 2008
drug discovery driven by patient population
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: GLG Expert Contributor
Drug discovery driven by patient population, revenue outcome and government willingness to  buy the product
July 21, 2008
multi target design ligands
Analysis of: Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease | www.fiercebiotech.com
Author: GLG Expert Contributor
 multi target design ligand
Volker HoffmannOctober 9, 2007
NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)
Analysis of: Study Finds NSF More Common Than Previously Reported | www.dimag.com
Author: Volker Hoffmann, Partner/Owner, Diagnostic Imaging Center
Nephrogenic systemic fibrosis is becoming a severe problem for radiologist and industry as it may prevent physicians from using gadolinium containing contrast agents fearing that they induce nephrogenic systemic fibrosis even in patients without known kidney disease. A stable contrast agent with almost...
Volker HoffmannMay 14, 2007
IMDS - CTML - Value without contrast agents?
Analysis of: Imaging Diagnostic Systems Breast Scanner Performance Upgrade Program Nearing Completion | www.medicalnewstoday.com
Author: Volker Hoffmann, Partner/Owner, Diagnostic Imaging Center
The recent upgrade of the Computed Tomography Laser Mammography (CTLM(R)) system will only added minor details. The question whether this system without any contrast agent is of any value has not been answered so far.

Previous Page : 1 2 3 Next11 to 20 of 21

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163